Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-HU6 in Healthy Male Subjects
NCT06325930Phase 1Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HU6 in obesity, metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF), sponsored by Rivus Pharmaceuticals, Inc. Primary endpoint: Mass Balance. Started Mar 2024; status: completed.
02
Drugs
HU6
03
Conditions
obesitymetabolic dysfunction-associated steatohepatitis (MASH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06325930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325930.